|
original article |
Date |
Title |
Authors All Authors |
1 |
[GO] |
2023―Mar―30 |
New-onset and flares of psoriasis after COVID-19 infection or vaccination successfully treated with biologics: a case series |
Luigi Gargiulo, Luciano Ibba, Carlo A. Vignoli, Francesco Piscazzi, Andrea Cortese, Giovanni Fiorillo, et al. (+6) Francesco Toso, Giulia Pavia, Mario Valenti, Jessica Avagliano, Alessandra Narcisi, Antonio Costanzo |
2 |
[GO] |
2023―Mar―17 |
High-risk Squamous Cell Carcinoma, a surgical challenge: the other face of the SARS-CoV-2 pandemic |
Alvaro Prados-Carmona, José María Llamas-Molina, Pablo Velasco-Amador, Ricardo Ruiz-Villaverde, José Carlos Ruiz-Carrascosa |
3 |
[GO] |
2023―Jan―10 |
Immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in patients receiving secukinumab: a literature review |
Paolo Gisondi, David Simon, Ivette Alarcon, Effie Pournara, Lluís Puig |
4 |
[GO] |
2022―Dec―22 |
Prevalence, risk and severity of SARS-CoV-2 infections in psoriasis patients receiving conventional systemic, biologic or topical treatment during the COVID-19 pandemic: a cross-sectional cohort study (PsoCOVID) |
K.V. Kwee, J. Murk, Q. Yin, M.B Visch, L. Davidson, E.M.G.J. de Jong, et al. (+2) J. M.P.A van den Reek, M. Tjioe |
5 |
[GO] |
2022―Jun―20 |
Letter to the editor submitted in response to ‘Incidence and prognosis of COVID-19 in patients with atopic diseases on dupilumab: a multicentre retrospective cohort study’ |
Maddalena Napolitano, Luca Potestio, Francesca Di Vico, Gabriella Fabbrocini, Cataldo Patruno |
6 |
[GO] |
2022―Apr―21 |
Incidence and prognosis of COVID-19 in patients with atopic diseases on dupilumab: a multicentre retrospective cohort study |
Brian D. Rankin, Jorge-Ryan Georgakopoulos, Muskaan Sachdeva, Asfandyar Mufti, Alim R. Devani, Melinda J. Gooderham, et al. (+6) Chih-Ho Hong, Vipul Jain, Perla Lansang, Ronald Vender, Jensen Yeung, Vimal H. Prajapati |
7 |
[GO] |
2022―Feb―16 |
Remote consultations: an audit of the management of dermatology patients on biologics during the first wave of the COVID-19 pandemic |
Chiedu E. Ufodiama, Sarah J. J. Touyz, David A. Fitzgerald, Hamish J. A. Hunter, Emma McMullen, Richard B. Warren, C. Elise Kleyn |
8 |
[GO] |
2021―Jun―29 |
Future perspectives on care for patients with psoriasis. What did we learn during the COVID-19 |
Peter C. M. van de Kerkhof |
9 |
[GO] |
2021―May―25 |
The impact of COVID-19 pandemic on psoriasis patients, and their immunosuppressive treatment: a cross-sectional multicenter study from Turkey |
Selda Pelin Kartal, Gökçen Çelik, Oğuz Yılmaz, Eda Öksüm Solak, Büşra Demirbağ Gül, Tuba Kevser Üstünbaş, et al. (+23) Melis Gönülal, Sevim Baysak, Esma İnan Yüksel, Begüm Ünlü, Münevver Güven, Ali Bozdağ, Gökhan Çınar, Selim Kartal, Murat Borlu, Müge Güler Özden, Burhan Engin, Server Serdaroğlu, Didem Didar Balcı, Bilal Doğan, Demet Çiçek, Ayça Cordan Yazıcı, Sema Aytekin, Neslihan Şendur, Hayriye Sarıcaoglu, Nida Gelincik Kaçar, Asena Cigdem Doğramacı, Levent Dönmez, Erkan Alpsoy |
10 |
[GO] |
2021―Mar―24 |
Risk of COVID-19 Infection, Hospitalization, and Mortality in Patients with Psoriasis Treated by Interleukin-17 Inhibitors |
Khalaf Kridin, Yochai Schonmann, Arie Solomon, Giovanni Damiani, Dana Tzur Bitan, Erez Onn, et al. (+2) Orly Weinstein, Arnon D. Cohen |
11 |
[GO] |
2021―Feb―10 |
My patient refers smell/taste disturbance. It may not be COVID-19. Dermatological drugs associated with olfactory and/or gustative disorders |
Luiz Guilherme Martins Castro, Isabella Parente Almeida |
12 |
[GO] |
2021―Jan―26 |
Immunosuppressants, Immunomodulators and COVID-19 Vaccines: Anticipating Patient Concerns |
Jonathan Rick, Alyssa M. Thompson, Jennifer L. Hsiao, Wilson Liao, Vivian Y. Shi |
13 |
[GO] |
2020―Dec―30 |
Estimating the susceptibility to SARS-CoV-2 infection with rituximab use for pemphigus vulgaris |
Zainab A. Jafri, Shikha Walia, Mirjana G. Ivanic, Jashin J. Wu |
14 |
[GO] |
2020―Dec―15 |
The prevalence of SARS-CoV-2 infection and the severity of the course of COVID-19 in patients with psoriasis treated with biologic therapy |
P Ciechanowicz, K Dopytalska, A Mikucka-Wituszyńska, M Dźwigała, K Wiszniewski, W Herniczek, et al. (+2) E Szymańska, I Walecka |
15 |
[GO] |
2020―Oct―23 |
COVID-19 in 3 patients treated with immune checkpoint inhibitors for advanced melanoma |
M. Arenbergerova, S. Gkalpakiotis, P. Arenberger, A. Fialova, M. Pasek |
16 |
[GO] |
2020―Oct―15 |
Strategies to maximize clinical efficiency while maintaining patient safety during the COVID-19 pandemic: an interview-based study from private practice dermatologists |
Kaitlyn M. Yim, Rebecca M. Yim, Sara Gaspard, Jamie MacDougall, April W. Armstrong |
17 |
[GO] |
2020―Sep―07 |
Evaluation of anxiety and depression in patients with morphea taking immunosuppressive drugs during the COVID-19 pandemic |
Mohammad Shahidi Dadras, Zohreh Ahmadzadeh, Shima Younespour, Fahimeh Abdollahimajd |
18 |
[GO] |
2020―Sep―03 |
Urticaria and COVID-19 infection: a critical appraisal- Reply |
Mohammed Shanshal |
19 |
[GO] |
2020―Sep―03 |
The reduction in the detection of melanoma during the coronavirus disease 2019 (COVID-19) pandemic in a Melanoma center of South Italy |
Alessia Villani, Gabriella Fabbrocini, Massimiliano Scalvenzi |
20 |
[GO] |
2020―Aug―12 |
Psychological teleconsultations in patients suffering from chronic skin diseases during the COVID-19 era: a service to improve patients’ quality of life |
Claudio Marasca, Anna De Rosa, Gabriella Fabbrocini, Mariateresa Cantelli, Angela Patrì, Maria Vastarella, et al. (+4) Lucia Gallo, Francesca di Vico, Serena Poggi, Angelo Ruggiero |
21 |
[GO] |
2020―Aug―08 |
Intralesional antigen immunotherapy for warts in the era of COVID-19 |
Ahmad Nofal, Mohamed M Fawzy, Ayman Abdelmaksoud, Esraa E El-Hawary |
22 |
[GO] |
2020―Aug―08 |
Urticaria and COVID-19 infection: a critical appraisal |
Yashdeep Singh Pathania |
23 |
[GO] |
2020―Aug―08 |
Examining recommendations for the use of biologics and other systemic therapies during COVID-19: a review and comparison of available dermatology guidelines and patient registries |
Mary Beth Gadarowski, Esther A. Balogh, Arjun M. Bashyam, Steven R. Feldman |
24 |
[GO] |
2020―Aug―08 |
Photo-triage of infantile haemangiomas: potential to reduce healthcare exposure in the COVID19 pandemic |
A Flynn, C O’Connor, M Murphy |
25 |
[GO] |
2020―Aug―04 |
Change of dermatological practice after the COVID-19 outbreak resolves |
Chuang Gao, Baoyi Liu, Yongyi Xie, Zhouwei Wu |
26 |
[GO] |
2020―Jul―29 |
The dermatology and aesthetic practices in the era of COVID-19 |
Khaled El-Hoshy, Mona El-Kalioby |
27 |
[GO] |
2020―Jul―29 |
COVID-19 and skin cancer management: French nation-wide questionnaire survey from real-life practice |
Charlée Nardin, Eve Puzenat, Sophie Dalac, Eve Maubec, François Aubin |
28 |
[GO] |
2020―Jul―29 |
Treatment of Severe Pemphigus vulgaris during COVID-19 pandemic |
Yashdeep Singh Pathania, Abhishek Bhardwaj |
29 |
[GO] |
2020―Jul―29 |
Nonsteroidal anti-inflammatory drugs (NSAIDs) consideration by dermatologists during the COVID19 pandemic |
Mohamed L. Elsaie, Mohammad Jafferany, Etleva Jorgaqi |
30 |
[GO] |
2020―Jul―29 |
Egyptian Dermatologists Attitude towards Telemedicine amidst the COVID19 Pandemic: A Cross-Sectional Study |
Mohamed L. Elsaie, Hany A Shehata, Noha S Hanafi, Shady M Ibrahim, Hany S Ibrahim, Ayman Abdelmaksoud |
31 |
[GO] |
2020―Jul―24 |
The impact of COVID-19 pandemic in a cohort of Italian psoriatic patients treated with biological therapies |
Federico Pirro, Giacomo Caldarola, Andrea Chiricozzi, Sara Tambone, Marco Mariani, Laura Calabrese, et al. (+3) Dario Francesco D’Urso, Clara De Simone, Ketty Peris |
32 |
[GO] |
2020―Jul―22 |
Rituximab: a safe therapeutic option during the COVID-19 pandemic? |
Ambra Di Altobrando, Annalisa Patrizi, Diego Abbenante, Federico Bardazzi |
33 |
[GO] |
2020―Jul―21 |
A case of severe psoriatic erythroderma with COVID-19 |
Fariba Ghalamkarpour, Mohammad Reza Pourani, Fahimeh Abdollahimajd, Omid Zargari |
34 |
[GO] |
2020―Jul―10 |
Low- dose systemic steroids, an emerging therapeutic option for COVID-19 related urticaria |
Mohammed Shanshal |
35 |
[GO] |
2020―Jul―09 |
Patient's perspective: psychological burden of the COVID-19 pandemic in 146 psoriatic patients treated with biological drugs and small molecules in real clinical practice |
A. Rodríguez-Villa Lario, D. Vega-Díez, M. González-Cañete, I. Polo-Rodríguez, A. B. Piteiro-Bermejo, M. Herrero-Fernández, et al. (+3) J. Arévalo-Serrano, L. Trasobares-Marugán, S. Medina-Montalvo |
36 |
[GO] |
2020―Jul―09 |
Treating hidradenitis suppurativa during the COVID-19 pandemic: teledermatology exams of sensitive body areas |
Chidubem A. V. Okeke, William D. Shipman, Jessica D. Perry, Michelle L. Kerns, Ginette A. Okoye, Angel S. Byrd |
37 |
[GO] |
2020―Jul―06 |
A probable atypical skin manifestation of COVID-19 infection |
Mohammad Shahidi Dadras, Omid Zargari, Rozita Abolghasemi, Ayda Bahmanjahromi, Fahimeh Abdollahimajd |
38 |
[GO] |
2020―Jul―06 |
COVID-19 related anagen effluvium |
Mohammed Shanshal |
39 |
[GO] |
2020―Jul―01 |
Cosmetic surgeries amidst pandemic area of COVID-19: suggested protocol |
Seyed-Naser Emadi, Amir Hooshang Ehsani, Kamran Balighi, Maryam Nasimi |
40 |
[GO] |
2020―Jun―30 |
Dermatological consultations in the COVID-19 era: Is teledermatology the key to social distancing? An Egyptian experience |
Pakinam I.N. Mostafa, Amira Ali Hegazy |
41 |
[GO] |
2020―Jun―30 |
The impact of COVID-19 pandemics on dermatologic surgery: real-life data from the Italian Red-Zone |
Laura Cristina Gironi, Paolo Boggio, Roberto Giorgione, Giovanni Damiani, Paola Savoia |
42 |
[GO] |
2020―Jun―29 |
COVID-19 and Psoriasis: Biologic Treatment and Challenges |
Ali Ebrahimi, Babak Sayad, Zohreh Rahimi |
43 |
[GO] |
2020―Jun―27 |
COVID-19 in pemphigus vulgaris patients with previous rituximab therapy: A tele-medicine experience |
Mohammad Shahidi-Dadras, Fahimeh Abdollahimajd, Laya Ohadi, Mohammadreza Tabary, Farnaz Araghi, Nikoo Mozafari, et al. (+2) Parviz Toosi, Sahar Dadkhahfar |
44 |
[GO] |
2020―Jun―27 |
Herpes zoster cases increased during COVID-19 outbreak. Is it possible a relation? |
Goksen Ertugrul, Habibullah Aktas |
45 |
[GO] |
2020―Jun―27 |
Epidermolysis bullosa and the COVID-19 pandemic: challenges and recommendations |
Hassan Vahidnezhad, Hamideh Moravvej, Ayda Bahmanjahromi, Leila Youssefian, Fahimeh Abdollahimajd |
46 |
[GO] |
2020―Jun―27 |
Treatment of Psoriasis - Unburdened by Fear During SARS-CoV2 Menace |
Teodora-Larisa Timis, Ioan-Alexandru Florian, Stefan-Cristian Vesa, Remus-Ioan Orasan |
47 |
[GO] |
2020―Jun―26 |
COVID-19 effect on phototherapy treatment utilization in dermatology |
S. Fisher, M. Ziv |
48 |
[GO] |
2020―Jun―22 |
Phototherapy and vitamin D: the importance in COVID-19 era |
Matteo Megna, Gabriella Fabbrocini, Alessia Villani |
49 |
[GO] |
2020―Jun―22 |
Clinical management of psoriasis patients during the COVID-19 pandemic |
Vipawee S. Chat, Shelley K. Uppal, Donovan G. Kearns, Jashin J. Wu |
50 |
[GO] |
2020―Jun―22 |
Organization of biologic therapy during the COVID-19 pandemic based on example of Dermatology Clinic Centre of Postgraduate Medical Education in Warsaw |
Klaudia Dopytalska, Agata Mikucka-Wituszyńska, Piotr Ciechanowicz, Michał Szczerba, Elżbieta Szymańska, Irena Walecka |
51 |
[GO] |
2020―Jun―22 |
Psoriasis and COVID-19: a multifactorial consideration |
Jeffrey M. Cohen, Lourdes M. Perez-Chada, Dimitri De Kouchkovsky, Jeff R. Gehlhausen |
52 |
[GO] |
2020―Jun―16 |
Psoriasis and risk of the COVID-19 infection: Is there a role for Angiotensin Converting Enzyme (ACE)? |
Mohammad Shahidi-Dadras, Mohammadreza Tabary, Reza M Robati, Farnaz Araghi, Sahar Dadkhahfar |
53 |
[GO] |
2020―Jun―13 |
Short-term stress-related increasing cases of alopecia areata during the COVID-19 pandemic |
Ömer Kutlu, Habibullah Aktaş, Işıl Göğem İmren, Ahmet Metin |
54 |
[GO] |
2020―Jun―10 |
Recommendations on trichological treatments during COVID-19 pandemic |
Alfredo Rossi, Francesca Magri, Gemma Caro, Alessandro Federico, Marco Di Fraia, Marta Muscianese, et al. (+2) Maria Caterina Fortuna, Marta Carlesimo |
55 |
[GO] |
2020―Jun―05 |
Challenges faced by patients with morphea in the era of SARS-CoV-2 |
Mohammad Shahidi Dadras, Nastaran Namazi, Mohammad Nikvar, Fahimeh Abdollahimajd |
56 |
[GO] |
2020―May―27 |
Use of systemic therapies for psoriasis in the COVID-19 era |
Donovan G. Kearns, Shelley Uppal, Vipawee S. Chat, Jashin J. Wu |
57 |
[GO] |
2020―May―21 |
Dermatology Department: What we could do amidst the pandemic of COVID-19? |
Robabeh Abedini, Narges Ghandi, Vahideh Lajevardi, Maryam Ghiasi, Maryam Nasimi |
58 |
[GO] |
2020―May―20 |
Is Biologic Treatment of Hidradenitis Suppurativa During the COVID-19 Pandemic Different from Psoriasis Biologic Treatment? |
Elia Rosi, Nicola Pimpinelli, Francesca Prignano |
59 |
[GO] |
2020―May―18 |
Management Strategies of Autoimmune bullous diseases during the Outbreak of 2019 Novel Coronavirus Disease (COVID-19) |
Pan Chen, Guiying Zhang, Yi Zhan |
60 |
[GO] |
2020―May―18 |
Safety of dupilumab in atopic patients during COVID-19 outbreak |
Maddalena Napolitano, Cataldo Patruno, Angelo Ruggiero, Mariateresa Nocerino, Gabriella Fabbrocini |
61 |
[GO] |
2020―May―18 |
Reorganization of a Northern Italy dermatology department during the COVID-19 pandemic: is it temporary or the beginning of a new era in dermatology? |
M. Valenti, L. Gargiulo, G. Pavia, P. Facheris, R. Borroni, A. Narcisi, A. Costanzo |
62 |
[GO] |
2020―May―14 |
Biologics for patients affected by Hidradenitis suppurativa in the COVID-19 era: data from a referral centre of Southern Italy |
Claudio Marasca, Angelo Ruggiero, Matteo Megna, Maria Carmela Annunziata, Gabriella Fabbrocini |
63 |
[GO] |
2020―May―14 |
A survey of psoriasis patients on biologics during COVID-19: a single centre experience |
M. Burlando, L. Carmisciano, E. Cozzani, A. Parodi |
64 |
[GO] |
2020―May―04 |
Inpatient Teledermatology During the COVID-19 Pandemic |
Kyle Rismiller, Alexander M. Cartron, John C. L. Trinidad |
65 |
[GO] |
2020―May―02 |
A challenging case of psoriasis flare-up after COVID-19 infection |
Soheila Nasiri, Farnaz Araghi, Mohammadreza Tabary, Mehdi Gheisari, Zahra Mahboubi-Fooladi, Sahar Dadkhahfar |
66 |
[GO] |
2020―May―02 |
Mucous membrane pemphigoid and COVID-19 treated with high-dose intravenous immunoglobulins: a case-report |
Maryam Daneshpazhooh, Tahereh Soori, Ahdie Isazade, Pedram Noormohammadpour |
67 |
[GO] |
2020―Apr―29 |
The Danger of Neglecting Melanoma during the COVID-19 Pandemic |
Tamar Gomolin, Abigail Cline, Marc Zachary Handler |
68 |
[GO] |
2020―Apr―28 |
Conducting Clinical Trials During the COVID-19 Pandemic |
EK. Collier, JL. Hsiao, VY. Shi |
69 |
[GO] |
2020―Apr―23 |
Immunomodulators and immunosuppressants in the era of SARS-CoV-2 - could laboratory tests be the missing link? |
Miguel Alpalhão, Paulo Filipe |
70 |
[GO] |
2020―Apr―17 |
Biologics for psoriasis patients in the COVID-19 era: more evidence, less fears |
M. Megna, A. Ruggiero, C. Marasca, G. Fabbrocini |
71 |
[GO] |
2020―Apr―13 |
The management of biologics in dermatologic patients in the 2019-nCoV era |
Kerasia-Maria Plachouri, Sophia Georgiou |
72 |
[GO] |
2020―Apr―08 |
SECURE-Psoriasis: a de-identified registry of psoriasis patients diagnosed with COVID-19 |
Esther A. Balogh, Courtney Heron, Steven R. Feldman, William W. Huang |
73 |
[GO] |
2020―Apr―07 |
Biological treatment use amid the COVID-19 era, a close look at the unresolved perplexity |
Mohammed Shanshal |
74 |
[GO] |
2020―Apr―06 |
Biologic therapy for psoriasis during the covid-19 outbreak is not a choice |
Federico Bardazzi, Camilla Loi, Lidia Sacchelli, Ambra Di Altobrando |
75 |
[GO] |
2020―Apr―03 |
COVID-19: Challenges and opportunities for dermatology response |
S Chawla |
76 |
[GO] |
2020―Apr―02 |
Teledermatology: a useful tool to fight COVID-19 |
Alessia Villani, Massimiliano Scalvenzi, Gabriella Fabbrocini |
77 |
[GO] |
2020―Apr―02 |
An Assessment of United States Dermatology Practices during the COVID-19 Outbreak |
Suraj Muddasani, Anne Housholder, Alan B. Fleischer |
78 |
[GO] |
2020―Mar―28 |
Biological treatment during COVID-19 outbreak |
Won Sriwijitalai, Viroj Wiwanitkit |
79 |
[GO] |
2020―Mar―19 |
Should patients stop their biologic treatment during the COVID-19 pandemic |
Arjun M. Bashyam, Steven R. Feldman |